{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:03Z","timestamp":1792511463356,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Dasatinib-induced chylothorax is a rare but potentially serious complication, and its clinical features remain poorly defined. This study aimed to systematically evaluate its clinical characteristics, therapeutic approaches, and patient outcomes to provide practical guidance for clinical management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective analysis by systematically retrieving case reports of dasatinib-induced chylothorax from relevant databases up to 31 May 2025, to achieve a comprehensive assessment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 24 patients from 22 published case reports and case series were included in this analysis. The median age was 50 years (range 5, 79), and the median time to onset of chylothorax following dasatinib initiation was 41 months (range 1, 168). The most frequently reported clinical symptom was dyspnea (62.5%), followed by fever (25.0%), cough (16.7%), abdominal pain (8.3%), and chest pain (4.2%). Pleural fluid was typically described as white and milky in appearance (87.5%). Biochemical analysis revealed a median pleural fluid triglyceride concentration of 547.4\u00a0mg\/dL and an albumin level of 4.4\u00a0g\/dL. Dasatinib therapy was discontinued in 83.3% of patients. Alternative tyrosine kinase inhibitors were prescribed in selected cases, including nilotinib (33.3%), imatinib (20.8%), and bosutinib (16.7%). Supportive treatments consisted primarily of corticosteroids (45.8%), diuretics (45.8%), and thoracentesis (29.2%). Clinical improvement was observed in 91.7% of patients, with a median time to recovery of 12.2 weeks (range 1, 52). Among the four patients who underwent dasatinib rechallenge, three experienced recurrence of chylothorax.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Dasatinib-induced chylothorax is rare but often reversible. Early diagnosis, drug discontinuation, and appropriate supportive care are key to recovery. Rechallenge should be undertaken cautiously due to a high risk of recurrence.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1665484","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:27:01Z","timestamp":1759123621000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical characteristics and management of dasatinib-induced chylothorax: retrospective analysis based on case reports"],"prefix":"10.3389","volume":"16","author":[{"given":"Ya","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani","year":"2023","journal-title":"Blood Adv."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.chest.2022.06.012","article-title":"Multidisciplinary management of chylothorax","volume":"162","author":"Agrawal","year":"2022","journal-title":"Chest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e231653","DOI":"10.1136\/bcr-2019-231653","article-title":"Chylothorax: complication attributed to dasatinib use","volume":"12","author":"Al-Abcha","year":"2019","journal-title":"BMJ Case Rep."},{"key":"B4","first-page":"74","article-title":"Dasatinib-induced chylothorax in chronic myeloid leukemia","volume":"1","author":"Alqattan","year":"2022","journal-title":"Gulf J. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ccm.2025.02.004","article-title":"Chylothorax","volume":"46","author":"Armas-Villalba","year":"2025","journal-title":"Clin. Chest Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/08998280.2017.11929535","article-title":"Dasatinib-induced chylothorax in chronic myeloid leukemia","volume":"30","author":"Baloch","year":"2017","journal-title":"Proc. Bayl Univ. Med. Cent."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1172\/jci17929","article-title":"Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors","volume":"111","author":"Bergers","year":"2003","journal-title":"J. Clin. Invest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"003601","DOI":"10.12890\/2022_003601","article-title":"A dasatinib-induced chylothorax persisting after the discontinuation of dasatinib","volume":"9","author":"Bradt","year":"2022","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3324\/haematol.2011.041251","article-title":"Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib","volume":"96","author":"Breccia","year":"2011","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/1061186x.2019.1616297","article-title":"Role of Co- and post-translational modifications of sfks in their kinase activation","volume":"28","author":"Cai","year":"2020","journal-title":"J. Drug Target"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s10637-020-00932-3","article-title":"Dasatinib-induced chylothorax: report of a case and review of the literature","volume":"38","author":"Chen","year":"2020","journal-title":"Invest. New Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/jco.2015.64.8899","article-title":"Final 5-year study results of dasision: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/jco.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized bfore trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4103\/1817-1737.191871","article-title":"Dasatinib-induced pleural effusion: chylothorax, an option to consider","volume":"11","author":"Ferreiro","year":"2016","journal-title":"Ann. Thorac. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/jco.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult philadelphia-positive all","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"003921","DOI":"10.12890\/2023_003921","article-title":"Dasatinib-induced chylothorax beyond 5 Years of treatment: is there actually any limit?","volume":"10","author":"Garcia-Zamalloa","year":"2023","journal-title":"Eur. J. Case Rep. Intern Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1097\/mph.0000000000001619","article-title":"Dasatinib-induced chylothorax in chronic myelogenous leukemia in pediatric patient: report of a case and review of literature","volume":"42","author":"Hickman","year":"2020","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e00753","DOI":"10.1002\/rcr2.753","article-title":"Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review","volume":"9","author":"Hsu","year":"2021","journal-title":"Respirol. Case Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4274\/tjh.2012.0196","article-title":"Dasatinib-related chylothorax","volume":"32","author":"Huang","year":"2015","journal-title":"Turk J. Haematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e071456","DOI":"10.1136\/bmjopen-2022-071456","article-title":"Fluid retention-associated adverse events in patients treated with bcr::abl1 inhibitors based on fda adverse event reporting system (faers): a retrospective pharmacovigilance study","volume":"13","author":"Huang","year":"2023","journal-title":"BMJ Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00277-024-05760-6","article-title":"Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different tki in patients with chronic phase cml","volume":"103","author":"Jain","year":"2024","journal-title":"Ann. Hematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e27503","DOI":"10.1002\/ppul.27503","article-title":"Dasatinib-induced chylothorax treated with diuretics and steroids","volume":"60","author":"Justin","year":"2025","journal-title":"Pediatr. Pulmonol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40265-016-0677-x","article-title":"Dasatinib: a review in chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e938319","DOI":"10.12659\/ajcr.938319","article-title":"Diagnostic pitfalls of chylothorax after dasatinib treatment of chronic myeloid leukemia","volume":"23","author":"Kelly","year":"2022","journal-title":"Am. J. Case Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1515\/pp-2023-0016","article-title":"Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with cml-cp","volume":"9","author":"K\u00fc\u00e7\u00fckyurt","year":"2024","journal-title":"Pleura Perit."},{"key":"B26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.21037\/tcr-22-1983","article-title":"Dasatinib-associated chylothorax in a pediatric patient with chronic myeloid leukemia: a case report and literature review","volume":"12","author":"Liu","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"101662","DOI":"10.1016\/j.rmcr.2022.101662","article-title":"Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia","volume":"37","author":"Makimoto","year":"2022","journal-title":"Respir. Med. Case Rep."},{"key":"B28","first-page":"76","article-title":"Dasatinib-induced chylothorax: a clinical laboratory's perspective","volume":"34","author":"Mart\u00ednez","year":"2023","journal-title":"Ejifcc"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e68479","DOI":"10.7759\/cureus.68479","article-title":"Dasatinib-induced bilateral chylothorax: a case report","volume":"16","author":"McGonegal","year":"2024","journal-title":"Cureus"},{"key":"B30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.arbres.2020.05.001","article-title":"Chylothorax secondary to dasatinib","volume":"56","author":"Molina","year":"2020","journal-title":"Arch. Bronconeumol. Engl. Ed."},{"key":"B31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/14782715241237577","article-title":"Drug-induced chylothorax as a rare pleural complication in dasatinib therapy for chronic myeloid leukaemia","volume":"54","author":"Ng","year":"2024","journal-title":"J. R. Coll. Physicians Edinb"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e41328","DOI":"10.1097\/md.0000000000041328","article-title":"Low-dose dasatinib-induced chylothorax, pulmonary hypertension, and pericardial effusion in a patient with chronic myeloid leukemia: a case report and literature review","volume":"104","author":"Pai","year":"2025","journal-title":"Med. Baltim."},{"key":"B33","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/jha2.226","article-title":"Dasatinib-induced chylothorax: an unusual presentation of a common adverse event-a case report with literature review","volume":"2","author":"Paul","year":"2021","journal-title":"EJHaem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.critrevonc.2013.10.005","article-title":"Large granular lymphocytosis, and pleural effusion: useful or adverse effect?","volume":"89","author":"Paydas","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1182\/blood.2023020399","article-title":"The hemorrhage risk of dasatinib therapy","volume":"141","author":"Pontarollo","year":"2023","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.rmed.2019.08.014","article-title":"Clinical approach and review of causes of a chylothorax","volume":"157","author":"Riley","year":"2019","journal-title":"Respir. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.2169\/internalmedicine.3002-19","article-title":"Successful control of dasatinib-related chylothorax by the Japanese herbal medicine goreisan","volume":"58","author":"Sasaki","year":"2019","journal-title":"Intern Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.cmet.2024.01.018","article-title":"Methionine secreted by tumor-associated pericytes supports cancer stem cells in clear cell renal carcinoma","volume":"36","author":"Zhang","year":"2024","journal-title":"Cell Metab."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1665484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:27:02Z","timestamp":1759123622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1665484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":38,"alternative-id":["10.3389\/fphar.2025.1665484"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1665484","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"article-number":"1665484"}}